Compare CLPS & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLPS | FGEN |
|---|---|---|
| Founded | 2005 | 1993 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.8M | 35.6M |
| IPO Year | 2018 | 2014 |
| Metric | CLPS | FGEN |
|---|---|---|
| Price | $0.85 | $9.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $146.50 |
| AVG Volume (30 Days) | 17.2K | ★ 26.2K |
| Earning Date | 10-17-2025 | 11-10-2025 |
| Dividend Yield | ★ 14.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 53.38 |
| Revenue | ★ $164,481,414.00 | $8,298,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.16 |
| Revenue Growth | ★ 15.17 | N/A |
| 52 Week Low | $0.82 | $4.85 |
| 52 Week High | $1.88 | $21.94 |
| Indicator | CLPS | FGEN |
|---|---|---|
| Relative Strength Index (RSI) | 43.24 | 54.76 |
| Support Level | $0.86 | $8.37 |
| Resistance Level | $0.95 | $9.09 |
| Average True Range (ATR) | 0.03 | 0.54 |
| MACD | -0.00 | 0.22 |
| Stochastic Oscillator | 3.50 | 61.29 |
CLPS Inc. is an IT consulting and solutions provider serving international clients in the banking, wealth management, e-commerce, and automotive sectors. The company drives digital transformation using AI, cloud computing, and big data, offering IT consulting, customized solutions, virtual banking training, recruitment, professional training, and software services. It operates mainly in two segments: IT services, which generate the majority of its revenue, and academic education services. The company has a presence in Hong Kong, Singapore, Mainland China, India, Malaysia, and Japan, with the majority of its revenue coming from Mainland China.
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.